相似文献
1
Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Path to a Dengue Vaccine: Learning from Human Natural Dengue Infection Studies and Vaccine Trials.
Cold Spring Harb Perspect Biol. 2018 Jun 1;10(6):a029371. doi: 10.1101/cshperspect.a029371.
2
The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
Asian Pac J Allergy Immunol. 2015 Sep;33(3):182-8. doi: 10.12932/AP0508.33.3.2015.
3
Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies.
J Virol. 2015 Jul;89(14):7348-62. doi: 10.1128/JVI.00273-15.
4
The Molecular Specificity of the Human Antibody Response to Dengue Virus Infections.
Adv Exp Med Biol. 2018;1062:63-76. doi: 10.1007/978-981-10-8727-1_5.
5
Dengue vaccine candidates in development.
Curr Top Microbiol Immunol. 2010;338:129-43. doi: 10.1007/978-3-642-02215-9_10.
6
A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone.
Expert Rev Vaccines. 2016;15(4):497-508. doi: 10.1586/14760584.2016.1128328. Epub 2016 Feb 22.
7
Immune response to dengue virus and prospects for a vaccine.
Annu Rev Immunol. 2011;29:587-619. doi: 10.1146/annurev-immunol-031210-101315.
8
Delineating the serotype-specific neutralizing antibody response to a live attenuated tetravalent dengue vaccine.
Vaccine. 2018 Apr 25;36(18):2403-2410. doi: 10.1016/j.vaccine.2018.03.055. Epub 2018 Mar 27.
9
Guiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccine.
Cell Mol Immunol. 2016 Jan;13(1):36-46. doi: 10.1038/cmi.2015.76. Epub 2015 Oct 5.
10
Dengue human infection models to advance dengue vaccine development.
Vaccine. 2015 Dec 10;33(50):7075-82. doi: 10.1016/j.vaccine.2015.09.052. Epub 2015 Sep 28.
引用本文的文献
1
Vaccination strategies, public health impact and cost-effectiveness of dengue vaccine TAK-003: A modeling case study in Thailand.
PLoS Med. 2025 Jun 17;22(6):e1004631. doi: 10.1371/journal.pmed.1004631. eCollection 2025 Jun.
2
Multivalent administration of dengue E dimers on liposomes elicits type-specific neutralizing responses without immune interference.
NPJ Vaccines. 2025 Jun 9;10(1):119. doi: 10.1038/s41541-025-01179-w.
3
Dengue severity by serotype and immune status in 19 years of pediatric clinical studies in Nicaragua.
PLoS Negl Trop Dis. 2025 Jan 10;19(1):e0012811. doi: 10.1371/journal.pntd.0012811. eCollection 2025 Jan.
4
Dengue virus IgG and neutralizing antibody titers measured with standard and mature viruses are protective.
Nat Commun. 2025 Jan 2;16(1):191. doi: 10.1038/s41467-024-53916-9.
5
Multiplex sample-sparing assay for detecting type-specific antibodies to Zika and dengue viruses: an assay development and validation study.
Lancet Microbe. 2025 Feb;6(2):100951. doi: 10.1016/j.lanmic.2024.07.014. Epub 2024 Dec 25.
6
Long term T cell response and safety of a tetravalent dengue vaccine in healthy children.
NPJ Vaccines. 2024 Oct 17;9(1):192. doi: 10.1038/s41541-024-00967-0.
7
Dengue virus IgG and serotype-specific neutralizing antibody titers measured with standard and mature viruses are associated with protection.
Res Sq. 2024 Apr 12:rs.3.rs-4145863. doi: 10.21203/rs.3.rs-4145863/v1.
8
Effect of previous heterologous flavivirus vaccinations on human antibody responses in tick-borne encephalitis and dengue virus infections.
J Med Virol. 2023 Nov;95(11):e29245. doi: 10.1002/jmv.29245.
9
Homotypic antibodies target novel E glycoprotein domains after natural DENV 3 infection/vaccination.
Cell Host Microbe. 2023 Nov 8;31(11):1850-1865.e5. doi: 10.1016/j.chom.2023.10.004. Epub 2023 Oct 30.
10
Phase 1 trial to model primary, secondary, and tertiary dengue using a monovalent vaccine.
BMC Infect Dis. 2023 May 23;23(1):345. doi: 10.1186/s12879-023-08299-5.
本文引用的文献
1
Dissecting Antibodies Induced by a Chimeric Yellow Fever-Dengue, Live-Attenuated, Tetravalent Dengue Vaccine (CYD-TDV) in Naive and Dengue-Exposed Individuals.
J Infect Dis. 2017 Feb 1;215(3):351-358. doi: 10.1093/infdis/jiw576.
2
Challenges to the Design of Clinical Trials for Live-Attenuated Tetravalent Dengue Vaccines.
PLoS Negl Trop Dis. 2016 Aug 11;10(8):e0004854. doi: 10.1371/journal.pntd.0004854. eCollection 2016 Aug.
3
Functional Transplant of a Dengue Virus Serotype 3 (DENV3)-Specific Human Monoclonal Antibody Epitope into DENV1.
J Virol. 2016 Apr 29;90(10):5090-5097. doi: 10.1128/JVI.00155-16. Print 2016 May 15.
4
Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort.
Proc Natl Acad Sci U S A. 2016 Jan 19;113(3):728-33. doi: 10.1073/pnas.1522136113. Epub 2016 Jan 4.
5
Dengue vaccine: hypotheses to understand CYD-TDV-induced protection.
Nat Rev Microbiol. 2016 Jan;14(1):45-54. doi: 10.1038/nrmicro.2015.2. Epub 2015 Dec 7.
6
Genotypic Differences in Dengue Virus Neutralization Are Explained by a Single Amino Acid Mutation That Modulates Virus Breathing.
mBio. 2015 Nov 3;6(6):e01559-15. doi: 10.1128/mBio.01559-15.
7
A new quaternary structure epitope on dengue virus serotype 2 is the target of durable type-specific neutralizing antibodies.
mBio. 2015 Oct 13;6(5):e01461-15. doi: 10.1128/mBio.01461-15.
8
Dengue viruses cluster antigenically but not as discrete serotypes.
Science. 2015 Sep 18;349(6254):1338-43. doi: 10.1126/science.aac5017.
9
Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease.
N Engl J Med. 2015 Sep 24;373(13):1195-206. doi: 10.1056/NEJMoa1506223. Epub 2015 Jul 27.
10
DENGUE VIRUS. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers.
Science. 2015 Jul 3;349(6243):88-91. doi: 10.1126/science.aaa8651.
Zotero 插件